Comparison of 18F-Fluciclovine PET versus 18F-Fluoroethyltyrosine PET in patients with newly diagnosed cerebral gliomas, recurrent cerebral gliomas and brain metastases – an open label single centre single arm prospective basket trial

Who can take part

• Patient is ≥ 18 years old
• Patient is mentally and physically able to understand the significance and scope of the study and to comply with the study staff
• Patient has decision-making capacity: capable of giving consent, insight, and information
• Patient has signed a written informed consent form prior to participation in the study
• Patient is referred to the Nuclear Medicine Clinic of the University Hospital Aachen for FET PET of the brain based on the prescription of the treating physicians
• Patient has suspected glioma prior to biopsy or surgery. OR
• Patient has suspected tumour recurrence after previous treatment for cerebral glioma or brain metastasis

Who cannot take part

• Patient has insufficiently controlled epilepsy
• Patient is pregnant or breastfeeding
• Patient is not willing to take adequately safe contraceptive measures
• Patient is institutionalised due to official or court order
• Patient is in a dependent relationship or employment relationship with the sponsor, investigator or his or her deputy
• Patient is unable to lie still for 40 minutes